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We have recently read with interest the paper by Torres-
Roca and colleagues (1); some relevant issues related to 
treatment tailoring on the basis of molecular signatures may 
raise considering showed results.
Briefly, a molecular signature estimating radiosensitivity 
(RSI), previously validated in a clinical context (2), was 
evaluated on 343 patients who underwent breast conservative 
therapy (BCT) and whole-breast radiotherapy (RT). Authors 
integrated RSI with tumor molecular subtypes, defined 
as luminal A (LUMA), luminal B (LUMB), luminal HER 
(LUMHER), Triple-negative (TN) and Human Epidermal 
Growth Receptor Factor 2 (HER2) positive, according to the 
expression level of genes ESR1, PR, ERBB2 and AURKA. 
The purpose of this analysis was refining classification of 
local recurrence (LR) risk in the study population.
Results showed that TN patients with RSI radioresistant 
score (RSI-R) patients had an increased risk of LR (HR =0.37; 
P=0.02), while TN RSI sensitive/intermediate (RSI-S/I) had 
a LR rate similar as LUMA and LUMB patients (HR =0.86; 
P=0.63). Age (P=0.001) and combined RSI-molecular 
subtype (P=0.004) were the most significant predictors of LR 
at multivariate analysis. Furthermore, RSI-R status was also 
a predictor of LR rate in estrogen receptor (ER) negative 
patients (HR =0.33; P=0.02), while no difference were found 
by RSI status in ER positive patients.
Currently, tumor stage, nodal status and histopathology 
guide breast cancer (BC) patient management, but a deeper 
knowledge of tumor cell biology, integrating both the 
information about risk of recurrence and response to RT, 
could change this paradigm.
Classifying BC on the basis of RSI may allow different 
treatment strategies for RSI-R and RSI-S/I tumors, 
including a de-escalation of adjuvant systemic treatment in 
selected patients.
Data from EBTCG meta-analysis showed that the risk of 
any recurrence at 10 years in a 50–60-year old, T2 N0, ER 
negative patient is 34% after BCT (3); according to results 
of Torres-Roca et al. (1), a similar patient with an RSI-S/I 
molecular arrangement could have a significantly lower 
recurrence risk, influencing treating physician in the choice 
of the adequate systemic management after radiation.
Speculation about showed results could also influence 
RT target volumes, because issues about RSI of tumor cells 
may concern tumor cells hosted in regional lymph nodes. 
Indeed, several recent studies demonstrated the benefit of 
adjuvant regional nodal irradiation (RNI), suggesting that 
eradication of subclinical nodal disease could reduce both 
local and distant failures (4,5).
In this context, data about the value of RSI status as a 
LR predictor in ER negative patients, could help to identify 
a BC subgroup in which the intrinsic radioresistance of 
tumor cells may overcome clinical gain of RNI, requiring a 
systemic approach rather than an aggressive local therapy. 
Given the potential side effects of RNI (potential increased 
symptomatic pneumonitis, arm edema, transient brachial 
plexus neuropathy, and ischemic heart disease), tailoring 
treatment strategy on molecular basis could allow to spare 
unnecessary toxicity, when RSI status may predict a lower 
benefit after RNI (6,7).
Furthermore, the results of ACOSOG Z0011 and 
IBSCG 23-01 trials (8,9) showed that selected patients with 
clinically negative axillae and 1–2 positive sentinel nodes 
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can safely omit axillary nodal dissection (ALND). However, 
information to determine when to include regional fields 
in treatment volume may be reduced is still limited, but a 
molecular signature predictive of RSI could help to choose 
the correct management in patients who omitted ALND.
In their analysis (1), the authors underlined that 
LUMA-B patients with RSI-R score had a lower LR rate if 
treated with dose >66 Gy; this result is of particular interest, 
considering that patients in 66 Gy group had a significantly 
higher rate of positive surgical margins and lymph node 
positive disease. Indeed, these patients are more likely to 
benefit from a dose escalation protocol, but more data on 
homogeneous population are needed in order to confirm 
this trend. Of course, as underlined by authors, dose-effect 
considerations about this study cohort are limited by the 
fact that patients were treated since 1984, comprehending 
non-computed tomography (CT)-based techniques 
and without the opportunity to assess the actual dose 
distribution of treatment plans.
Due to the increasing complexity of techniques, factors 
such as dose per fraction, dose homogeneity, and dose rate 
have to be considered in order to relate biological effects of 
prescribed dose to intrinsic RSI of tumor cells population.
In our opinion is crucial to point out that uniform 
treatment technique and thorough quality assurance 
assessment should be encouraged, in particular when 
radiobiological issues are in play, because differences in 
technique, dose prescription, reporting, and delivery could 
heavily affect study results.
Anyway, results from this study showed a differentiated 
impact in molecular subtypes by RSI status, suggesting 
distinct patterns of radioresistance in different subgroups. 
Thus, impact of radiation exposure may have a different 
biological effect on different BC molecular subtypes, and this 
could reasonably influence the clinical outcome of treatment. 
Trying to identify RSI patterns could be interesting, since 
many biomarker of radioresistance have been identified, 
with molecular targets potentially able to increase effects of 
radiation exposure of specific BC cell populations.
For example, EGFR family proteins showed to be 
overexpressed after repeated radiation exposures of 2 Gy, 
and these effects are confirmed for HER2, suggesting that 
response to radiation may be biologically related to ERBB2 
expression (10). In vitro and in vivo experiences confirmed 
that HER2 silenced BC cell lines had increased RSI, and 
that HER2 xenograft tumors had enhanced radioresistance 
if compared to corresponding controls. These effects on 
RSI seemed to be related to HER2 mediated up-regulation 
of phosphorylation of focal adhesion kinase (FAK); as a 
counterproof, RSI was restored using a FAK inhibitor (11).
Interestingly, Torres-Roca et al. (1) reported that RT 
dose did not affect LR in LUM-HER RSI-R group, while 
dose response effect was significant in LUMA-B RSI-R 
patients (RT dose 66 Gy; HR =0.13; 95% CI: 0.02–1.01). 
Thus, clinical evidence supports the HER2 effect on RSI of 
BC tumors, indicating that HER2 patients are not likely to 
benefit from dose escalation protocols.
On the other hand, TN BC are considered to be 
radioresistant if compared to others subtypes (12), but TN 
RSI-S/I and LUMA-B patients were found to have a similar 
LR rate in the mentioned paper, suggesting that TN tumors 
could have a wide range of RSI.
Some molecular targets showed to be overexpressed in 
TN BC, such as the maternal embryonic leucine zipper 
kinase (MELK), a serine/threonine kinase involved in cell 
survival to exogenous stress (13). MELK showed to be 
related to radiation induced DNA double strand damage 
repair and stem cell self-renewal (14), and knockdown cell 
lines and in vivo models showed increased RSI and delayed 
tumor growth (15).
In the present paper, RSI-S/I status was related to lower 
LR in TN molecular subtypes and ER negative patients, 
and we may argue that in this population, MELK expression 
could be a crucial step in influencing RSI. Therefore to relate 
the RSI score to the abovementioned biomarkers may be 
a further step in order to reach a better knowledge on how 
different cancer cell line can overcome radiation damage.
Finally another issue to consider is the impact of 
biological therapy on such a complex scenario. Both 
concomitant and sequential use of targeted systemic agents 
is current standard in adjuvant treatment of BC; this could 
directly impact on response to radiation exposure, but also 
influence biological behavior of cells surviving to RT.
For example, HER2 positive cells are more likely to 
be resistant to radiation damage, regardless of RSI score 
status, but sensitive to anti-HER2 treatment administration. 
Due to the heterogeneity of HER2 expression within 
the tumor, RT could eradicate HER2 negative and select 
HER2 positive clones. Thus, we can assume that, in 
HER2 positive patients, RT and trastuzumab could have a 
synergistic effect. Such hypothesis, although attractive, are 
only speculative, but enhance once more the complexity of 
implementing a RSI score in clinical practice.
Nowadays intensity of adjuvant treatment and tailoring 
of therapies on the basis of biology do represent critical 
issues for the clinical oncologist (16,17).
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Understanding the clinical meaning of these considerations 
is challenging, but integration between clinical, molecular, 
radiobiological and technical aspects is necessary, in order to 
develop an effective tailored approach to the patient.
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